Overview
CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analog. The 'DAC' (Drug Affinity Complex) modification binds the peptide to serum albumin, extending its half-life from minutes to roughly 6–8 days. This produces a sustained 'GH bleed' — a steady elevation of growth hormone and IGF-1 rather than the natural pulsatile release.
Mechanism of action
CJC-1295 binds GHRH receptors in the anterior pituitary, stimulating endogenous GH release. The DAC modification prevents enzymatic degradation, allowing one weekly dose to maintain elevated GH/IGF-1 levels continuously.
Reported benefits
- Sustained increase in growth hormone and IGF-1
- Improved body composition (lean mass gain, fat reduction)
- Enhanced sleep depth and quality
- Better skin elasticity and recovery
- Convenient weekly dosing schedule
Research dosing
Research protocols typically use 1–2 mg subcutaneously once weekly. Cycles of 8–16 weeks are common.
Considerations
The sustained 'GH bleed' contrasts with pulsatile peptides like Ipamorelin or no-DAC CJC. Some researchers prefer no-DAC variants paired with Ipamorelin for more physiologic pulses; others prefer DAC for convenience.
Research use only. This article is provided for educational purposes and is not medical advice. Products sold on this website are for laboratory research only and are not intended for human consumption. Not evaluated by the FDA.
Continue reading